Introduction
Introduction Statistics Contact Development Disclaimer Help
Return Create A Forum - Home
---------------------------------------------------------
nCoV_info
https://ncovinfo.createaforum.com
---------------------------------------------------------
*****************************************************
Return to: vaccine
*****************************************************
#Post#: 301--------------------------------------------------
effectivity
By: gsgs Date: June 15, 2021, 12:34 am
---------------------------------------------------------
[code]
effectivity in England 1,2 doses
symp hosp
BNT-alpha, 47,94 83,95 68,12
AZ--alpha, 49,74 76,86 52,47
BNT-delta, 36,88 94,96 90,66 78
AZ--delta, 30,67 71,92 59,75 65
40,81 78,92 65,50 71
symp-BNT-alpha,47,94
symp-AZ--alpha,49,74
hosp-BNT-alpha,83,95
hosp-AZ--alpha,76,86
symp-BNT-delta,36,88
symp-AZ--delta,30,67
hosp-BNT-delta,94,96
hosp-AZ--delta,71,92
efficacy
symp hosp death death|symp
BNT ,87,95 --,--
BNT ,--,90 --,-- --,97 44,--
AZ- ,--,87 80,-- 55,--
BNT>80, --,93
----------------------------------------------------
PHE-v23.pdf
alpha,symp, 50,88
delta,symp, 33,81
infe symp trans hosp death
BNT-alpha, 62,80 62,87 47,-- 80,92 77,97
AZ--alpha, 65,-- 62,77 42,-- 80,-- 77,--
----------------------------------------------------
England
BNT-alpha, 47,94 83,95
AZ--alpha, 49,74 76,86
BNT-delta, 36,88 94,96
AZ--delta, 30,67 71,92
----------------------------------------------------
Michigan
10880-0dose,825-1dose,129-2dose
hosp seve
40,90 -03,16
----------------------------------------------------
Qatar
infe seve
BNT-alpha, --,89 --,97
BNT-351 , --,75 --,97
------------------------------------------------
[/code]
alpha=B.1.1.7 (Kent)
delta=B.1.617.2 (India)
beta?=B.1.351 (South Africa)
gamma?=P.1 (Brazil)
*****************************************************
You are viewing proxied material from gopher.createaforum.com. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.